CD274 and adenocarcinoma: Gandhi et al. demonstrated that mNSCLC patients with adenocarcinoma who received four cycles of a platinum-based doublet chemotherapy with pembrolizumab, followed by pembrolizumab and pemetrexed, had improved mOS to platinum/pemetrexed, regardless of the PDL-1 expression level [10].